The US FDA has approved pablizumab (Keytruda) as an adjuvant treatment for early-stage non-small cell lung cancer. In the trial, pablizumab (Keytruda) significantly prolonged cancer-free survival in patients compared to placebo.
Data from a study recently published by the Royal Marsden Cancer Centre showed promising data for the combination of Avutometinib + Defactinib in the treatment of ovarian cancer, resulting in significant tumour shrinkage in 28% of patients and disease control in 93% of patients.
In recommendations released on 2 February 2023, the National Comprehensive Cancer Network (NCCN) recommends that doctors consider neratinib for patients with HER2-negative metastatic breast cancer, regardless of their estrogen receptor status.
Preoperative oxaliplatin-fluoropyrimidine chemotherapy given to colon cancer patients did not increase the risk of perioperative complications in colon cancer patients and did reduce postoperative recurrence rates, according to the results of the international phase 3/4 FOxTROT trial.
Osteoporosis is the cause of menopausal fractures! Do these 5 things to avoid osteoporosis
We all know that we need to pay attention to our diet after suffering from a disease, because improper diet will affect the recovery of the disease and the health of the patient.
There are many ways to treat prostate cancer and radiation therapy is a common treatment for prostate cancer, but many prostate cancer patients want to know what the side effects of radiation therapy are.
There is an urgent clinical need for new antimicrobial drugs to break through the dilemma of cIAI treatment in children and address the growing challenge of drug resistance.
Approval for new FIC depression drug on the horizon!
Pancreatic cancer is known to be a highly fatal and incurable type of cancer known as the "king of cancers". Currently, the only possible cure for pancreatic cancer is the complete surgical removal of the tumour tissue. Once the cancer has spread beyond the pancreatic organ, the patient's treatment options are very limited.
